Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML

(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news